16 
It was also brought out before the Health Subcoirimittee 
that NIII did not even knov ; all of the companies engaged in 
recombinant DMA technology. The Department of Agriculture 
had not responded to Fredrickson ' s query at that time. And is 
it not also possible that some of the many investigators sup- 
ported by funds other than those from NIK or MSF at universi- 
ties or other research institutions, including a small frac- 
tion supported from personal funds, will choose not to con- 
form to the Guidelines? One scientist told me personally that 
he thought the Guidelines were ridiculous — that he believed 
the unfettered freedom of inquiry and the acquisition knowl- 
edge far outweighed the importance of subjecting the public 
to even potentially serious risks to its collective health. 
It would be extraordinarily idealistic to assume that all 
will be as conscientious, responsible and respectful of the 
Guidelines as assumed by those within NIH, who believe so much 
in the inherent good in man to expect voluntary compliance 
with the Guidelines from all quarters. 
This tone of optimistic idealism v/hich runs through the 
impact statement was also expressed to me in a letter of 17 
March, 1976, from Dr. Maxine Singer of NIH, who is of the 
opinion that I am incorrect in questioning the motives and 
the effect they may have upon the performance and integrity 
of those in private industry. However, the published 
record of the testing of prescription drugs for both 
Appendix K — 70 
